Josh Lehrer, M.D., M.Phil., FACC

As CEO of Marea Therapeutics, Josh bridges his clinical background as a practicing physician with decades of experience at global biopharmaceutical companies leading businesses and high-functioning teams across all stages of drug development.
 
Previously, Josh served as CEO of Graphite Bio, building the company and team from seed funding to IPO. Before that, he was chief medical officer at Global Blood Therapeutics, where he led the innovative clinical development strategy for sickle cell disease treatment Oxbryta® (voxelotor) from pre-IND stages through commercial launch, including playing an integral role in raising more than $1 billion to fund the product’s development and launch. At Global Blood, Josh also built a 45-member development organization and oversaw all clinical development and operations for the company during a period of rapid growth and pipeline advancement. He has also served in leadership roles at Genentech in clinical development and business development, as well as attending physician roles at Stanford University Medical Center and the Palo Alto Veteran’s Affairs Health System.
 
Josh holds an M.D. from the University of California, San Francisco School of Medicine and completed his residency at UCSF in internal medicine. He holds an A.B. in biochemical sciences from Harvard University and a Master of Philosophy in biological sciences from the University of Cambridge. Josh served as a clinical and postdoctoral fellow in cardiovascular medicine at Stanford University and attended the Institute for Entrepreneurship at the Stanford Graduate School of Business.